Eureka Therapeutics and City of Hope Treat First Patient with GPC3 Targeting ARTEMIS® T Cells (ECT204) for Advanced Liver Cancer

Eureka Therapeutics, Inc. and City of Hope announced that City of Hope treated the first patient with GPC3-positive advanced hepatocellular carcinoma, the predominant type of liver cancer, with ECT204, an experimental T cell therapy.